Physician profile
Anne M Barnes
NPI 1649897406
$3,994.60
in general payments reported to CMS, 2019-2025
28 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,331 · 2022: $454 · 2023: $21.16 · 2024: $816 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.28 |
| Education | $259.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $810.00 | 2021 | |
| Janssen Biotech, INC. | $420.85 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $413.12 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $297.89 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $268.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Astrazeneca Pharmaceuticals Lp | $235.14 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.10 | 2024-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $215.03 | 2021-2025 | Omvoh |
| Genzyme Corporation | $172.94 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $148.42 | 2021-2024 | Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.88 | 2021-2023 | Jardiance |
| Gilead Sciences, INC. | $75.05 | 2024-2025 | |
| Pfizer INC. | $70.65 | 2021-2024 | |
| Celgene Corporation | $68.88 | 2024 | Zeposia |
| Novo Nordisk INC | $64.93 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $51.54 | 2024-2025 | Voquezna |
| Abbott Laboratories | $50.77 | 2022 | |
| Paratek Pharmaceuticals, INC. | $45.77 | 2021-2022 | |
| Corium, LLC | $37.64 | 2022 | |
| Janssen Scientific Affairs, LLC | $33.16 | 2024 | |
| Eisai INC. | $30.66 | 2021 | |
| Vanda Pharmaceuticals INC. | $30.48 | 2021 | |
| Orphalan INC | $29.99 | 2025 | Cuvrior |
| Biohaven Pharmaceuticals, INC. | $27.24 | 2021 | |
| Aimmune Therapeutics, INC. | $23.34 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $21.74 | 2025 | |
| Ardelyx, INC. | $15.94 | 2025 | Ibsrela |
| Amgen INC. | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.